Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

ETIOSARC study : environmental aetiology of sarcomas from a French prospective multicentric population-based case-control study-study protocol.

Lacourt A, Amadéo B, Gramond C, Marrer E, Plouvier S, Baldi I, Blay JY, Coindre JM, de Pinieux G, Gouin F, Italiano A, Le Cesne A, Le Loarer F, Monnereau A, Pellegrin I, Penel N, Ray-Coquard I, Toulmonde M, Ducimetière F, Mathoulin-Pélissier S; Etiosarc study group.

BMJ Open. 2019 Jun 18;9(6):e030013. doi: 10.1136/bmjopen-2019-030013.

2.

Multimorbidity, age-related comorbidities and mortality: association of activation, senescence and inflammation markers in HIV adults.

Duffau P, Ozanne A, Bonnet F, Lazaro E, Cazanave C, Blanco P, Rivière E, Desclaux A, Hyernard C, Gensous N, Pellegrin I, Wittkop L.

AIDS. 2018 Jul 31;32(12):1651-1660. doi: 10.1097/QAD.0000000000001875.

PMID:
29762168
3.

A standardized flow cytometry procedure for the monitoring of regulatory T cells in clinical trials.

Pitoiset F, Barbié M, Monneret G, Braudeau C, Pochard P, Pellegrin I, Trauet J, Labalette M, Klatzmann D, Rosenzwajg M.

Cytometry B Clin Cytom. 2018 Sep;94(5):621-626. doi: 10.1002/cyto.b.21622. Epub 2018 Jan 23.

4.

Serum suppression of tumorigenicity 2 level is an independent predictor of all-cause mortality in HIV-infected patients.

Thiébaut R, Hue S, Le Marec F, Lelièvre JD, Dupon M, Foucat E, Lazaro E, Dabis F, Duffau P, Wittkop L, Surenaud M, Pellegrin I, Lacabaratz C, Bonnet F, Lévy Y; ANRS CO3 Aquitaine Cohort.

AIDS. 2017 Nov 13;31(17):2355-2365. doi: 10.1097/QAD.0000000000001628.

PMID:
29068834
5.

Activation, senescence and inflammation markers in HIV patients: association with renal function.

Ozanne A, Duffau P, Dauchy FA, Rigothier C, Terrien C, Lazaro E, Cazanave C, Lawson-Ayayi S, Bonnet F, Blanco P, Wittkop L, Pellegrin I; CIADIS sub-study in the ANRS CO3 Aquitaine cohort study group.

AIDS. 2017 May 15;31(8):1119-1128. doi: 10.1097/QAD.0000000000001461.

PMID:
28328797
6.

Integrative Analysis of Immunological Data to Explore Chronic Immune T-Cell Activation in Successfully Treated HIV Patients.

Picat MQ, Pellegrin I, Bitard J, Wittkop L, Proust-Lima C, Liquet B, Moreau JF, Bonnet F, Blanco P, Thiébaut R; ANRS CO3 Aquitaine Cohort.

PLoS One. 2017 Jan 3;12(1):e0169164. doi: 10.1371/journal.pone.0169164. eCollection 2017.

7.

Association of immune-activation and senescence markers with non-AIDS-defining comorbidities in HIV-suppressed patients.

Duffau P, Wittkop L, Lazaro E, le Marec F, Cognet C, Blanco P, Moreau JF, Dauchy FA, Cazanave C, Vandenhende MA, Bonnet F, Thiebaut R, Pellegrin I; ANRS CO3 Aquitaine Cohort Study Group.

AIDS. 2015 Oct 23;29(16):2099-108. doi: 10.1097/QAD.0000000000000807.

PMID:
26544576
8.

Effect of cytomegalovirus-induced immune response, self antigen-induced immune response, and microbial translocation on chronic immune activation in successfully treated HIV type 1-infected patients: the ANRS CO3 Aquitaine Cohort.

Wittkop L, Bitard J, Lazaro E, Neau D, Bonnet F, Mercie P, Dupon M, Hessamfar M, Ventura M, Malvy D, Dabis F, Pellegrin JL, Moreau JF, Thiébaut R, Pellegrin I; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.

J Infect Dis. 2013 Feb 15;207(4):622-7. doi: 10.1093/infdis/jis732. Epub 2012 Nov 29.

PMID:
23204178
9.

[Serological diagnosis of celiac disease].

Roujon P, Sarrat A, Contin-Bordes C, Pellegrin I, Guidicelli G, Taupin JL, Moreau JF, Blanco P.

Pathol Biol (Paris). 2013 Jun;61(3):e39-46. doi: 10.1016/j.patbio.2011.03.013. Epub 2011 May 28. Review. French.

PMID:
21621349
10.

Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort.

Wittkop L, Breilh D, Da Silva D, Duffau P, Mercié P, Raymond I, Anies G, Fleury H, Saux MC, Dabis F, Fagard C, Thiébaut R, Masquelier B, Pellegrin I; ANRS CO3 Aquitaine Cohort.

J Antimicrob Chemother. 2009 Jun;63(6):1251-5. doi: 10.1093/jac/dkp114. Epub 2009 Mar 31.

11.

Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy.

Wittkop L, Commenges D, Pellegrin I, Breilh D, Neau D, Lacoste D, Pellegrin JL, Chêne G, Dabis F, Thiébaut R.

BMC Med Res Methodol. 2008 Oct 22;8:68. doi: 10.1186/1471-2288-8-68.

12.

Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).

Pellegrin I, Wittkop L, Joubert LM, Neau D, Bollens D, Bonarek M, Girard PM, Fleury H, Winters B, Saux MC, Pellegrin JL, Thiébaut R, Breilh D; ANRS Co3 Aquitaine Cohort.

Antivir Ther. 2008;13(2):271-9.

PMID:
18505178
13.

Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network.

Chaix ML, Desquilbet L, Descamps D, Costagliola D, Deveau C, Galimand J, Goujard C, Signori-Schmuck A, Schneider V, Tamalet C, Pellegrin I, Wirden M, Masquelier B, Brun-Vezinet F, Rouzioux C, Meyer L; French PRIMO Cohort Study Group (ANRS CO 06); French ANRS AC11 Resistance Study Group.

Antivir Ther. 2007;12(8):1305-10.

PMID:
18240870
14.

Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients.

Pellegrin I, Breilh D, Coureau G, Boucher S, Neau D, Merel P, Lacoste D, Fleury H, Saux MC, Pellegrin JL, Lazaro E, Dabis F, Thiébaut R; ANRS Co3 Aquitaine Cohort.

Antimicrob Agents Chemother. 2007 Apr;51(4):1473-80. Epub 2007 Feb 12.

15.

Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study).

Djabarouti S, Breilh D, Pellegrin I, Lavit M, Camou F, Caubet O, Fleury H, Saux MC, Pellegrin JL.

J Antimicrob Chemother. 2006 Nov;58(5):1090-3. Epub 2006 Aug 18.

PMID:
16921181
16.

Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).

Pellegrin I, Breilh D, Ragnaud JM, Boucher S, Neau D, Fleury H, Schrive MH, Saux MC, Pellegrin JL, Lazaro E, Vray M.

Antivir Ther. 2006;11(4):421-9.

PMID:
16856615
17.

Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection.

Lazaro E, Coureau G, Guedj J, Blanco P, Pellegrin I, Commenges D, Dabis F, Moreau JF, Pellegrin JL, Thiébaut R; ANRS Co3 Aquitaine Cohort.

Antivir Ther. 2006;11(3):343-50.

18.

HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.

Ghosn J, Pellegrin I, Goujard C, Deveau C, Viard JP, Galimand J, Harzic M, Tamalet C, Meyer L, Rouzioux C, Chaix ML; French PRIMO Cohort Study Group (ANRS CO 06).

AIDS. 2006 Jan 9;20(2):159-70.

PMID:
16511408
19.

Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.

Benhamou Y, Fleury H, Trimoulet P, Pellegrin I, Urbinelli R, Katlama C, Rozenbaum W, Le Teuff G, Trylesinski A, Piketty C; TECOVIR Study Group.

Hepatology. 2006 Mar;43(3):548-55.

PMID:
16496322
20.

Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/microl? Impact on immunovirological parameters.

Pellegrin I, Thiébaut R, Blanco P, Viallard JF, Schrive MH, Merel P, Chêne G, Fleury H, Moreau JF, Pellegrin JL.

J Med Virol. 2005 Oct;77(2):164-72.

PMID:
16121362
21.

Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.

Molina JM, Chêuc G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM; ALBI (ANRS 070) Study Group.

Antivir Ther. 1999;4 Suppl 3:71-4.

PMID:
16021874
22.

French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002.

Descamps D, Chaix ML, André P, Brodard V, Cottalorda J, Deveau C, Harzic M, Ingrand D, Izopet J, Kohli E, Masquelier B, Mouajjah S, Palmer P, Pellegrin I, Plantier JC, Poggi C, Rogez S, Ruffault A, Schneider V, Signori-Schmück A, Tamalet C, Wirden M, Rouzioux C, Brun-Vezinet F, Meyer L, Costagliola D.

J Acquir Immune Defic Syndr. 2005 Apr 15;38(5):545-52.

PMID:
15793364
23.

Immunological markers after long-term treatment interruption in chronically HIV-1 infected patients with CD4 cell count above 400 x 10(6) cells/l.

Thiébaut R, Pellegrin I, Chêne G, Viallard JF, Fleury H, Moreau JF, Pellegrin JL, Blanco P.

AIDS. 2005 Jan 3;19(1):53-61.

24.

Simultaneous determination of the antiretroviral agents: amprenavir, lopinavir, ritonavir, saquinavir and efavirenz in human peripheral blood mononuclear cells by high-performance liquid chromatography-mass spectrometry.

Rouzes A, Berthoin K, Xuereb F, Djabarouti S, Pellegrin I, Pellegrin JL, Coupet AC, Augagneur S, Budzinski H, Saux MC, Breilh D.

J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Dec 25;813(1-2):209-16.

PMID:
15556535
25.

Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study).

Breilh D, Pellegrin I, Rouzés A, Berthoin K, Xuereb F, Budzinski H, Munck M, Fleury HJ, Saux MC, Pellegrin JL.

AIDS. 2004 Jun 18;18(9):1305-10.

PMID:
15362663
26.

Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France.

Chaix ML, Descamps D, Harzic M, Schneider V, Deveau C, Tamalet C, Pellegrin I, Izopet J, Ruffault A, Masquelier B, Meyer L, Rouzioux C, Brun-Vezinet F, Costagliola D.

AIDS. 2003 Dec 5;17(18):2635-43.

PMID:
14685058
27.

HIV type 1 isolates from 200 untreated individuals in Ho Chi Minh City (Vietnam): ANRS 1257 Study. Large predominance of CRF01_AE and presence of major resistance mutations to antiretroviral drugs.

Lan NT, Recordon-Pinson P, Hung PV, Uyen NT, Lien TT, Tien HT, Garrigue I, Schrive MH, Pellegrin I, Lafon ME, Aboulker JP, Barré-Sinousi F, Fleury HJ.

AIDS Res Hum Retroviruses. 2003 Oct;19(10):925-8.

PMID:
14601592
28.

Predictive value of provirus load and DNA human immunodeficiency virus genotype for successful abacavir-based simplified therapy.

Pellegrin I, Caumont A, Garrigue I, Merel P, Schrive MH, Fleury H, Dupon M, Pellegrin JL, Ragnaud JM.

J Infect Dis. 2003 Jan 1;187(1):38-46. Epub 2002 Dec 13.

PMID:
12508144
29.

Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).

Pellegrin I, Breilh D, Montestruc F, Caumont A, Garrigue I, Morlat P, Le Camus C, Saux MC, Fleury HJ, Pellegrin JL.

AIDS. 2002 Jul 5;16(10):1331-40.

PMID:
12131209
30.

Genotypic drug resistance during HIV-1 primary infection in France (1996-1999): frequency and response to treatment.

Harzic M, Pellegrin I, Deveau C, Chaix ML, Dubeaux B, Garrigue I, Ngo N, Rouzioux C, Goujard C, Hoen B, Sereni D, Delfraissy JF, Meyer L; PRIMO Study Group.

AIDS. 2002 Mar 29;16(5):793-6. No abstract available.

PMID:
11964538
31.

Comparison of capillary electrophoresis sequencing with the new CEQ 2000 DNA Analysis System to conventional gel based systems for HIV drug resistance analysis.

Merel P, Pellegrin I, Garrigue I, Caumont A, Schrive MH, Birac V, Bonot P, Fleury H.

J Virol Methods. 2001 Oct;98(1):9-16.

PMID:
11543879
32.

Pharmacokinetics and resistance mutations affect virologic response to ritonavir/saquinavir-containing regimens.

Pellegrin I, Breilh D, Birac V, Deneyrolles M, Mercié P, Trylesinski A, Neau D, Saux MC, Fleury HJ, Pellegrin JL.

Ther Drug Monit. 2001 Aug;23(4):332-40.

PMID:
11477313
33.

Monitoring and biomonitoring of surface ozone in Florence, Italy.

Nali C, Ferretti M, Pellegrin i M, Lorenzini G.

Environ Monit Assess. 2001 Jun;69(2):159-74.

PMID:
11465665
34.

Persistence of zidovudine-resistance mutations in HIV-1 isolates from patients removed from zidovudine therapy for at least 3 years and switched to a stavudine-containing regimen.

Pellegrin I, Garrigue I, Caumont A, Pellegrin JL, Merel P, Schrive MH, Bonot P, Fleury H.

AIDS. 2001 May 25;15(8):1071-3. No abstract available.

PMID:
11399996
35.

Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy.

Ngo-Giang-Huong N, Deveau C, Da Silva I, Pellegrin I, Venet A, Harzic M, Sinet M, Delfraissy JF, Meyer L, Goujard C, Rouzioux C; Frnech PRIMO Cohort Study Group.

AIDS. 2001 Apr 13;15(6):665-73.

PMID:
11371680
36.

Prognostic value of plasma markers of immune activation in patients with advanced HIV disease treated by combination antiretroviral therapy.

Savès M, Morlat P, Chêne G, Peuchant E, Pellegrin I, Bonnet F, Bernard N, Lacoste D, Salamon R, Beylot J.

Clin Immunol. 2001 Jun;99(3):347-52.

PMID:
11358430
37.

Cell-associated HIV-1-DNA quantitation after highly active antiretroviral therapy-treated primary infection in patients with persistently undetectable plasma HIV-1 RNA.

Garrigue I, Pellegrin I, Hoen B, Dumon B, Harzic M, Schrive MH, Séréni D, Fleury H.

AIDS. 2000 Dec 22;14(18):2851-5.

PMID:
11153666
38.

HIV RNA and HIV DNA in peripheral blood mononuclear cells are consistent markers for estimating viral load in patients undergoing long-term potent treatment.

Burgard M, Izopet J, Dumon B, Tamalet C, Descamps D, Ruffault A, Vabret A, Bargues G, Mouroux M, Pellegrin I, Ivanoff S, Guisthau O, Calvez V, Seigneurin JM, Rouzioux C.

AIDS Res Hum Retroviruses. 2000 Dec 10;16(18):1939-47.

PMID:
11153076
39.

Phenotypic resistance pattern of HIV-1 isolates with zidovudine and/or multidrug resistance mutations after didanosine-stavudine combination therapy.

Pellegrin I, Segondy M, Garrigue I, Izopet J, Montes B, Pellegrin JL, Reynes J, Massip P, Puel J, Fleury H.

J Acquir Immune Defic Syndr. 2000 Dec 15;25(5):465-6. No abstract available.

PMID:
11141248
40.

New molecular assays to predict occurrence of cytomegalovirus disease in renal transplant recipients.

Pellegrin I, Garrigue I, Ekouevi D, Couzi L, Merville P, Merel P, Chene G, Schrive MH, Trimoulet P, Lafon ME, Fleury H.

J Infect Dis. 2000 Jul;182(1):36-42. Epub 2000 Jun 27.

PMID:
10882579
41.

Dual nucleoside regimens in nonadvanced HIV infection: prospective follow-up of 130 patients, Aquitaine Cohort, 1996 to 1998. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).

Morlat P, Marimoutou C, Dequae-Merchadou L, Pellegrin I, Mercié P, Neau D, Beylot J, Dabis F.

J Acquir Immune Defic Syndr. 2000 Mar 1;23(3):255-60.

PMID:
10839661
42.

Once-daily administration of didanosine in combination with stavudine in antiretroviral-naive patients. The STADI Group.

Reynes J, Denisi R, Massip P, Izopet J, Pellegrin I, Segondy M.

J Acquir Immune Defic Syndr. 1999 Sep 1;22(1):103-5. No abstract available.

PMID:
10534154
43.

Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group.

Pellegrin I, Izopet J, Reynes J, Denayrolles M, Montes B, Pellegrin JL, Massip P, Puel J, Fleury H, Segondy M.

AIDS. 1999 Sep 10;13(13):1705-9.

PMID:
10509572
44.

Evaluation of new quantitative assays for diagnosis and monitoring of cytomegalovirus disease in human immunodeficiency virus-positive patients.

Pellegrin I, Garrigue I, Binquet C, Chene G, Neau D, Bonot P, Bonnet F, Fleury H, Pellegrin JL.

J Clin Microbiol. 1999 Oct;37(10):3124-32.

45.

The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus.

Molina JM, Chêne G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM.

J Infect Dis. 1999 Aug;180(2):351-8.

PMID:
10395849
46.

Vascular endothelial growth factor (VEGF165) plasma level increase with immunodepression in AIDS patients with Kaposi's sarcoma.

Mercié P, Devianne I, Viallard JF, Faure I, Pellegrin I, Leng B, Dupon M, Barbeau P, Fleury H, Pellegrin JL.

Microvasc Res. 1999 Mar;57(2):208-10. No abstract available.

PMID:
10049669
47.

Changes in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.

Chêne G, Binquet C, Moreau JF, Neau D, Pellegrin I, Malvy D, Ceccaldi J, Lacoste D, Dabis F.

AIDS. 1998 Dec 3;12(17):2313-20.

PMID:
9863874
48.
49.

Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy.

Dalod M, Harzic M, Pellegrin I, Dumon B, Hoen B, Sereni D, Deschemin JC, Levy JP, Venet A, Gomard E.

J Infect Dis. 1998 Jul;178(1):61-9.

PMID:
9652424
50.

CD4+ lymphocyte count and plasma HIV RNA levels in a survey of 1602 HIV-infected patients in Bordeaux, France, 1996-1997. Groupe d'Epidemiologie Clinique da SIDA en Aquitaine.

Marimoutou C, Chêne G, Pellegrin I, Moreau JF, Spira R, Neau D, Lacoste D, Ceccaldi J, Malvy D, Dabis F.

AIDS. 1998 May 28;12(8):962-4. No abstract available.

PMID:
9631157

Supplemental Content

Loading ...
Support Center